Polypharmacy on Healthy Aging in People Living With HIV Over the Age of 75

ConditionVirus-HIV
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age75+
SponsorCentre Hospitalier Universitaire de Nice

About this trial

Since the advent of antiretroviral treatments, the life expectancy of people living with HIV (PLHIV) has increased significantly. In France, more than 30% of PLHIV are now over 50 years old. This population is exposed to high multimorbidity, leading to frequent polypharmacy, defined as the regular use of at least five medications. Polypharmacy also has a qualitative dimension, including potentially inappropriate prescriptions. It increases the risk of adverse effects and drug interactions and impairs quality of life. A coordinated geriatric approach is therefore essential to optimize care. Healthy aging, promoted by the WHO, aims to improve the lives of older people. In this context, a study will be conducted at the Nice University Hospital among PLHIV aged 75 and over. It will collect quantitative data, the results of which will enable us to consider, if necessary, adapting the care pathways of these patients whose needs are complex.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

HIV-positive

Aged 75 or over

Affiliated with the social security system

Having expressed no objection to participating in the study

Disqualifiers

Refusal to participate

Known severe cognitive impairment preventing the interview from being conducted

Patient under guardianship or conservatorship

Trial design

Design model

Single group

Treatments tested in this trial

  • interview with advanced practice nurse

    Other intervention

    45 to 60 minutes of interview

Treatment groups

136 Participants
are divided into 1 treatment group
Group A: people living with HIV over the age of 75Other 1 intervention

Trial outcomes

Primary outcomes

1

Describe polypharmacy among people living with HIV aged 75 and older.

The average number of medications taken

Time frame
15 months

Secondary outcomes

1

Assess the most common comorbidities associated with polypharmacy in the population of PLHIV aged 75

Number et type of comorbidities

Time frame
15 months
2

Assess whether people taking multiple medications have a lower treatment adherence score than those taking fewer medications.

Score obtained on the Morisky MMAS-8 questionnaire

Time frame
15 months
3

Assess the level of functional independence in this age group and link it to the existence of polypharmacy.

Lawton and Brody IADL scale

Time frame
15 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.